Eli Lilly (NYSE:LLY) announced today that it acquired peptide- and protein-engineering platform developer Protomer Technologies.
The potential value of the transaction is over $1 billion, depending on the achievement of future development and commercial milestones.
Pasadena, Calif.–based Protomer Technologies develops next-generation protein therapeutics designed to identify and synthesize molecules that can sense glucose or other endogenous modulators of protein activity.
Get the full story at our sister site, Drug Delivery Business News.
Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development, Metabolic disease/endicrinology
Tell Us What You Think!
You must be logged in to post a comment.